|
Pazopanib (trade name Votrient) is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis. It has been approved for renal cell carcinoma and ] by numerous regulatory administrations worldwide.〔〔〔〔 ==Medical uses== It is approved by numerous regulatory administrations worldwide (including the FDA (19 October 2009), EMA (14 June 2010), MHRA (14 June 2010) and TGA (30 June 2010)) for use as a treatment for advanced/metastatic renal cell carcinoma and advanced soft tissue sarcomas. In Australia and New Zealand, it is subsidised under the PBS and by Pharmac respectively, under a number of conditions, including:〔(【引用サイトリンク】url= http://www.pharmac.govt.nz/Schedule?osq=Pazopanib )〕 * The medication is used to treat clear cell variant renal cell carcinoma. * The treatment phase is continuing treatment beyond 3-months. * The patient has been issued an authority prescription for pazopanib * The patient must have stable or responding disease according to the Response Evaluation Criteria In Solid Tumours (RECIST) * This treatment must be the sole tyrosine kinase inhibitor subsidised for this condition. It has also demonstrated initial therapeutic properties in patients with ovarian and non-small cell lung cancer, though plans to apply to the EMA for a variation to include advanced ovarian cancer have been withdrawn and a license will not be sought in any country. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「pazopanib」の詳細全文を読む スポンサード リンク
|